ClinicalTrials.gg
CompletedNCT00852670Updated Nov 13, 2009

ACT-128800 in Psoriasis

A Phase 2 interventional study of ACT-128800 and Placebo in Plaque Psoriasis, sponsored by Actelion. Completed at 14 sites in 5 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2009-11-13.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 76 studies in Psoriasis by Johnson & Johnson — 3 open to participants now, 12 under way, 7 of them phase 3. Psoriasis · Johnson & Johnson.

Enrollment
45th of 58
66 · median 222
Started
2008
with 2 others
Phase 2
12 of 76
none open now
Registered
17th of 76
by date

Among the 76 studies in Psoriasis by Johnson & Johnson, this one is the 45th largest by enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2008, is one of 12 in phase 2, and was the 17th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

3 of the 76 studies in Psoriasis by Johnson & Johnson are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Psoriasis by Johnson & Johnson, or all of them as a file.
02

Study summary

This study will assess the efficacy, safety, and tolerability of ACT-128800 in subjects with moderate to severe plaque psoriasis.

03

Conditions studied

  • Plaque Psoriasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult males and females with moderate to severe plaque psoriasis who require systemic treatment and for whom participation in a placebo-controlled study of an drug is justified.

Exclusion criteria

Exclusion Criteria:

  • Patients with other forms of psoriasis and patients who are currently treated for disorders other than psoriasis.
  • Systemic or topical treatments for psoriasis other than emollients.
  • Ongoing bacterial, viral or fungal infections.
  • History or presence of .
  • Additional inclusion and exclusion criteria apply with respect to medical conditions and concomitant treatments which could affect patients' risk from participating in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Experimental
    A

    Drug: ACT-128800

  • Placebo comparator
    B

    Drug: Placebo

Interventions

  • ACT-128800 administered orally once daily

  • DrugPlacebo

    Matching placebo capsules administered orally once daily

06

What researchers measure

Primary outcomes

  1. Psoriasis Area and Severity Index (PASI) percent change relative to baseline at Week 6 visit.

    Time frame: Baseline to week 6

Secondary outcomes

  1. "Clear - almost clear" Physician Global Assessment (PGA) at Week 6 visit.

    Time frame: Week 6

07

Study locations

14 sites
  • Landeskrankenhaus - Universitätsklilnikum Graz, Allgemeine Dermatologie
    Graz, 8036, Austria
  • University Klinik of Vienna
    Vienna, 1090, Austria
  • Departement de Pneumologie/ Unité Immunologie Clinique Allergie- Centre Hospitalier Lyon sud
    Lyon, 69000, France
  • CHU de Nice-Hôpital de l'Archet 2 / Service de dermatologie
    Nice, 6202, France
  • Dermatologie, Hôpital Purpan Universtité Paul Sabatier
    Toulouse, 31000, France
  • Klinik für Dermatologie Venerologie und Allergologie
    Berlin, 10117, Germany
  • Universitätsklinikum Hamburg-Eppendorf
    Hamburg, 20246, Germany
  • Department of Dermatology University Hospital Johannes Gutenberg-University Mainz
    Mainz, 55131, Germany
  • University Clinic Münster Clinic and Policlinic for skin diseases
    Muenster, 48149, Germany
  • Semmelweis Universtity Dept. dermato-venerology and skin oncology
    Budapest, 1085, Hungary
  • UNIVERSITY OF DEBRECEN Department of dermatology
    Debrecen, 4012, Hungary
  • University of Szeged Department of dermatology and allergology
    Szeged, 6720, Hungary
  • Veszprem County Csolnoky Ferenc Hospital Dermatology Department
    Veszprem, 8200, Hungary
  • Clinical Centre of Nis Clinic of Dermato-venerology
    Nis, 18000, Serbia
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2008, a primary completion of Jul 2009 and a completion of Sep 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2009
First posted
Feb 27, 2009
Start
Oct 2008
Primary completionActual
Jul 2009
CompletionActual
Sep 2009
Last update
Nov 13, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 13, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00852670
Lead sponsor
Actelion
First posted
Feb 27, 2009
Start date
Oct 2008
Primary completion
Jul 2009
Completion
Sep 2009
Last update
Nov 13, 2009

Study contacts

Albrecht Georg Schmidt, MD
study director · Actelion

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion